Agenda

Optimizing Endocrine and Targeted Therapy for Early Stage HR+/HER2- Breast Cancer

Claudine Isaacs, MD, FRCPC

‍

Decoding Gene Expression Assays for Early-Stage HR+/HER2- Therapy Planning

Adam M. Brufsky, MD, PhD

‍

Evolving Insights Related to Minimal Residual Disease Monitoring in Breast Cancer

Arielle Medford, MD

‍

How Obesity and Estrogen Changes at Menopause Impair Antitumor Immunity

Joyce Slingerland, MD, PhD

‍

Audience Q&A and Panel Discussion

Seth A. Wander, MD, PhD; Adam M. Brufsky, MD, PhD; Claudine Isaacs, MD, FRCPC; Arielle Medford, MD; Joyce Slingerland, MD, PhD